Blockade of NF-kappaB for Prevention/Treatment of GVHD
阻断 NF-κB 用于预防/治疗 GVHD
基本信息
- 批准号:7108055
- 负责人:
- 金额:$ 24.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-05-01 至 2007-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Allogeneic stem cell transplantation (allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma. However, the problems associated with graft-versus-host disease (GVHD) have greatly limited the use of allo-SCT to patients with either an HLA-identical family member or unrelated donor in many transplant centers. As a consequence, the development of new therapies that could prevent or treat GVHD would be a significant advance for patients needing an allo-SCT. Currently, the most common approaches to the prevention of GVHD are either a combination of S-phase active chemotherapy drug, such as methotrexate, and a calcineurin inhibitor or in vivo methods of T cell depletion using antibodies such as Campath -1H. While these approaches can induce T cell tolerance, they do not impact on the generation of proinflammatory cytokines and chemokines that are induced by conditioning therapy and critical to the development of GVHD. As most new therapies for the treatment or prevention of GVHD have arisen from studies in solid organ transplantation, which does not involve inflammation-inducing conditioning therapy, we believe a new approach that focuses specifically on allo-SCT and the complications of conditioning treatment are needed for new agents to be developed. NF-(B is a dimmer composed of Pel proteins and is critical in the induction of T cell tolerance and the generation of over 200 proteins involved in inflammation. Our group has previously found that poorly soluable drugs that target NF-(B have a modest effect on the occurrence of GVHD in animal models, that is greatly limited by the bioavailability of the compound. In this proposal, we have initiated a collaboration with the biotechnology company, TheraLogics, to evaluate the use of two agents licensed by the company in the prevention or treatment of GVHD. NEMO-binding peptides (NBD peptides) block the activation of NF-(B by interfering with the interaction of IKK( with IKK( and IKK(. The chief scientific officer of TheraLogics, Sankar Ghosh Ph.D. has previously found that this peptide can block osteoclastogenesis in murine models mediated by the activation of NF-(B. The second compound we will evaluate will be the IKKp inhibitor, Compound A, that has been licensed by TheraLogics from Bayer. This proposal brings together two extremely experienced investigators in the biology of GVHD, in Drs Serody and Blazar, with scientists at TheraLogics who are experts on the biology of NF-(B in Drs Baldwin and Ghosh. This approach may allow the generation of a number of new compounds that are both more effective and safer for the prevention or treatment of GVHD, which could significantly increase the use of allo-SCT for those individuals who could benefit from this therapy. If these phase I studies are successful, phase II studies will pave the way for clinical trials of this therapy at the University of North Carolina at Chapel Hill.
描述(由申请人提供):同种异体干细胞移植(Allogeneic stem cell transplantation, allo-SCT)是治疗白血病、淋巴瘤和多发性骨髓瘤的潜在疗法。然而,在许多移植中心,与移植物抗宿主病(GVHD)相关的问题极大地限制了对具有相同hla的家庭成员或非亲属供体的患者使用同种异体sct。因此,能够预防或治疗GVHD的新疗法的开发对于需要同种异体细胞移植的患者来说将是一个重大的进步。目前,预防GVHD最常见的方法要么是s期活性化疗药物(如甲氨蝶呤)与钙调磷酸酶抑制剂联合使用,要么是使用抗体(如Campath -1H)消耗T细胞的体内方法。虽然这些方法可以诱导T细胞耐受,但它们不会影响促炎细胞因子和趋化因子的产生,而促炎细胞因子和趋化因子是由调节疗法诱导的,对GVHD的发展至关重要。由于大多数治疗或预防GVHD的新疗法都来自实体器官移植的研究,而这些研究不涉及炎症诱导调节治疗,我们认为需要开发一种新的方法,专门针对同种异体细胞移植和调节治疗的并发症。NF-(B)是一种由Pel蛋白组成的调光剂,在诱导T细胞耐受和产生200多种与炎症有关的蛋白质中起关键作用。我们的研究小组先前发现,在动物模型中,针对NF-(B)的难溶性药物对GVHD的发生有一定的影响,这在很大程度上受到该化合物的生物利用度的限制。在该提案中,我们已经启动了与生物技术公司TheraLogics的合作,以评估该公司许可的两种药物在预防或治疗GVHD中的使用。nemo结合肽(NBD肽)通过干扰IKK(与IKK()和IKK()的相互作用来阻断NF-(B)的活化。TheraLogics的首席科学官Sankar Ghosh博士先前发现,这种肽可以阻断由NF-(B)激活介导的小鼠模型中的破骨细胞生成。我们将评估的第二个化合物是IKKp抑制剂,化合物A,已由拜耳TheraLogics许可。该提案将两位在GVHD生物学方面经验丰富的研究人员serdy博士和Blazar博士与TheraLogics的NF- B生物学专家Baldwin博士和Ghosh博士聚集在一起。这种方法可能会产生许多新的化合物,这些化合物在预防或治疗GVHD方面更有效、更安全,这可能会显著增加那些可能从这种治疗中受益的人使用同种异体细胞移植。如果这些I期研究成功,II期研究将为该疗法在北卡罗来纳大学教堂山分校的临床试验铺平道路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Patrick Michael Flood其他文献
Patrick Michael Flood的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Patrick Michael Flood', 18)}}的其他基金
Inhibition of IkK to treat lethal Graft-vs.-Host Disease
抑制 Ikk 可治疗致命的移植物抗宿主病
- 批准号:
7883853 - 财政年份:2009
- 资助金额:
$ 24.45万 - 项目类别:
NF-kB Inhibition of Lung Ischemia Repurfusion Injury
NF-kB对肺缺血再灌注损伤的抑制作用
- 批准号:
7750074 - 财政年份:2009
- 资助金额:
$ 24.45万 - 项目类别:
Inhibition of IkK to treat lethal Graft-vs.-Host Disease
抑制 Ikk 可治疗致命的移植物抗宿主病
- 批准号:
7481353 - 财政年份:2006
- 资助金额:
$ 24.45万 - 项目类别:
Inhibition of IkK to treat lethal Graft-vs.-Host Disease
抑制 Ikk 可治疗致命的移植物抗宿主病
- 批准号:
7643877 - 财政年份:2006
- 资助金额:
$ 24.45万 - 项目类别:
相似国自然基金
KCTD10对2型免疫反应(Th2)的调控研究
- 批准号:2020JJ4441
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
乙烯合酶ACS家族的AEF蛋白调节拟南芥开花时间的机制研究
- 批准号:31970735
- 批准年份:2019
- 资助金额:58.0 万元
- 项目类别:面上项目
USP13调控IL-18诱导的NF-κB活化的分子机制研究
- 批准号:31900556
- 批准年份:2019
- 资助金额:26.0 万元
- 项目类别:青年科学基金项目
let-7通过SOCS1调控巨噬细胞极化及其在前列腺癌进展中的作用
- 批准号:81560465
- 批准年份:2015
- 资助金额:38.0 万元
- 项目类别:地区科学基金项目
纳米微粒载NF-κB圈套基因对神经发育缺陷大鼠模型的干预研究
- 批准号:30870892
- 批准年份:2008
- 资助金额:8.0 万元
- 项目类别:面上项目
相似海外基金
Adjuvant effect of physical exercise on immune response to COVID-19 vaccination and interactions with stress
体育锻炼对 COVID-19 疫苗接种免疫反应的辅助作用以及与压力的相互作用
- 批准号:
10593597 - 财政年份:2023
- 资助金额:
$ 24.45万 - 项目类别:
Investigating the relationship between internalized weight stigma and metabolic syndrome
调查内在体重耻辱与代谢综合征之间的关系
- 批准号:
10502884 - 财政年份:2022
- 资助金额:
$ 24.45万 - 项目类别:
eHealth Supported Mindfulness-based Music Therapy Intervention (eMBMT) in Hemopoietic Stem Cell Transplant Patients
eHealth 支持造血干细胞移植患者的正念音乐治疗干预 (eMBMT)
- 批准号:
10701885 - 财政年份:2022
- 资助金额:
$ 24.45万 - 项目类别:
Investigating the relationship between internalized weight stigma and metabolic syndrome
调查内在体重耻辱与代谢综合征之间的关系
- 批准号:
10672239 - 财政年份:2022
- 资助金额:
$ 24.45万 - 项目类别:
eHealth Supported Mindfulness-based Music Therapy Intervention (eMBMT) in Hemopoietic Stem Cell Transplant Patients
eHealth 支持造血干细胞移植患者的正念音乐治疗干预 (eMBMT)
- 批准号:
10512325 - 财政年份:2022
- 资助金额:
$ 24.45万 - 项目类别:
Investigation of the Central and Peripheral Inflammatory Mechanisms of PTSD Onset
PTSD发病的中枢和外周炎症机制研究
- 批准号:
10707101 - 财政年份:2021
- 资助金额:
$ 24.45万 - 项目类别:
Investigation of the Central and Peripheral Inflammatory Mechanisms of PTSD Onset
PTSD发病的中枢和外周炎症机制研究
- 批准号:
10468470 - 财政年份:2021
- 资助金额:
$ 24.45万 - 项目类别:
Psychobiological stress vulnerability, executive control, and emotion regulation in children and adolescents with cancer
癌症儿童和青少年的心理生物学压力脆弱性、执行控制和情绪调节
- 批准号:
9892895 - 财政年份:2020
- 资助金额:
$ 24.45万 - 项目类别:
Psychobiological stress vulnerability, executive control, and emotion regulation in children and adolescents with cancer
癌症儿童和青少年的心理生物学压力脆弱性、执行控制和情绪调节
- 批准号:
10369008 - 财政年份:2020
- 资助金额:
$ 24.45万 - 项目类别:
Psychobiological stress vulnerability, executive control, and emotion regulation in children and adolescents with cancer
癌症儿童和青少年的心理生物学压力脆弱性、执行控制和情绪调节
- 批准号:
10591473 - 财政年份:2020
- 资助金额:
$ 24.45万 - 项目类别: